Liberum Capital reaffirmed their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note published on Wednesday morning. The firm currently has a GBX 1,900 ($24.21) price objective on the stock.
A number of other analysts have also issued reports on the stock. BNP Paribas reissued an underperform rating and set a GBX 1,520 ($19.37) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, March 22nd. Berenberg Bank set a GBX 1,890 ($24.08) target price on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research note on Monday, March 20th. Societe Generale reissued a sell rating and set a GBX 1,300 ($16.56) target price on shares of GlaxoSmithKline plc in a research note on Thursday, March 23rd. Morgan Stanley set a GBX 1,700 ($21.66) target price on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research note on Tuesday, May 2nd. Finally, HSBC Holdings plc reissued a buy rating and set a GBX 1,970 ($25.10) target price on shares of GlaxoSmithKline plc in a research note on Thursday, April 27th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of GBX 1,745.17 ($22.23).
GlaxoSmithKline plc (GSK) opened at 1695.50 on Wednesday. GlaxoSmithKline plc has a one year low of GBX 1,363.00 and a one year high of GBX 1,745.56. The firm has a 50-day moving average of GBX 1,653.76 and a 200 day moving average of GBX 1,606.74. The company’s market capitalization is GBX 82.84 billion.
ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline plc’s (GSK) “Buy” Rating Reiterated at Liberum Capital” was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2654090/glaxosmithkline-plcs-gsk-buy-rating-reiterated-at-liberum-capital.html.
The business also recently disclosed a dividend, which will be paid on Thursday, July 13th. Stockholders of record on Thursday, May 11th will be issued a dividend of GBX 19 ($0.24) per share. The ex-dividend date of this dividend is Thursday, May 11th. This represents a dividend yield of 1.21%.
In related news, insider Dominic Redfern acquired 230 shares of the business’s stock in a transaction dated Thursday, April 13th. The shares were purchased at an average price of GBX 1,639 ($20.88) per share, for a total transaction of £3,769.70 ($4,802.78). Also, insider Emma Walmsley acquired 83 shares of the business’s stock in a transaction dated Tuesday, April 18th. The shares were bought at an average price of GBX 1,647 ($20.98) per share, for a total transaction of £1,367.01 ($1,741.64). In the last 90 days, insiders have bought 662 shares of company stock worth $1,067,188.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.